Inclusion Criteria:

          -  Confirmed diagnosis of AML harboring a mutation in IDH2 relapsed or refractory to
             first line cytarabine/anthracycline induction chemotherapy, failed to respond to or
             relapsed following at least 2 cycles of hypomethylating agent (azacitidine,
             decitabine, sgi-110) or at least 1 cycle of hypomenthylating agent with venetoclax or
             other targeted therapies

               -  Patients will be identified and deemed eligible based upon the identification of
                  an IDH2 mutation identified at either at the time of disease relapse prior to
                  re-induction chemotherapy or following 1-2 cycles of chemotherapy induction. Each
                  institution will test using their standard local FDA-approved or cleared assay
                  per the institutional standard of care workup for relapsed disease.

               -  First relapse defined as untreated hematologic relapse (according to
                  International Working Group criteria) after one line of intensive regimen for AML
                  including at least one cytarabine containing induction block with a total dose no
                  less than 700 mg/m^2 per cycle and 3 days of an anthracycline that induced a
                  complete remission (CR)/complete remission with incomplete hematologic recovery
                  (CRi)/complete remission with incomplete platelet recovery (CRp). Subjects are
                  allowed to receive induction, consolidation, transplant and/or maintenance
                  therapy prior to achieving their first CR/CRi/CRp

               -  Refractory to induction therapy is defined as never achieving CR, CRi or CRp
                  (according to International Working Group criteria) after one line of intensive
                  regimen for AML (reinduction, consolidation and/or transplant allowed) including
                  at least one cytarabine containing induction block with a total dose no less than
                  700 mg/m^2 per cycle and 3 days of an anthracycline

          -  Subjects considered eligible for intensive chemotherapy

          -  Subjects had received a first salvage within the last 60 days (day 15 to 60 following
             most recent cytarabine-based standard salvage number [#] 1 therapy) who achieved
             either > 50% reduction in blast percentage from the pre-treatment bone marrow OR < 20%
             cellularity with any blast percentage AND < 5% peripheral blood blasts

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2

          -  Adequate liver function within 72 hours of enrollment, defined as:

             o Blood total bilirubin ≤ 1.5 x ULN, unless considered due to Gilbert's syndrome (eg,
             a gene mutation in UGT1A1) or leukemic organ involvement, following review by the
             Investigator

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x upper
             limit of normal (ULN) (within 72 hours of enrollment)

          -  Adequate renal function within 72 hours of enrollment, defined as blood creatinine =<
             2.5 x ULN

          -  Females of childbearing potential (FCBP) may participate, providing they meet the
             following conditions:

               -  Agree to practice true abstinence from sexual intercourse or to use highly
                  effective contraceptive methods (eg, combined [containing estrogen and
                  progestogen] or progestogen-only associated with inhibition of ovulation, oral,
                  injectable, intravaginal, patch, or implantable hormonal contraceptive; bilateral
                  tubal occlusion; intra-uterine device; intrauterine hormone-releasing system; or
                  male partner sterilization [note that vasectomized partner is a highly effective
                  birth control method provided that partner is the sole sexual partner of the FCBP
                  trial participant and that the vasectomized partner has received medical
                  assessment of the surgical success]) at screening and throughout the study, and
                  for 4 months following the last study treatment (6 months following the last dose
                  of cytarabine); and

               -  Have a negative serumblood β-subunit of human chorionic gonadotropin (β-hCG)
                  pregnancy test (sensitivity of at least 25 mIU/mL) at screening; and

               -  Have a negative serum or urine (investigator's discretion under local
                  regulations) β hCG pregnancy test (sensitivity of at least 25 mIU/mL) within 72
                  hours prior to the start of study treatment in the Treatment Phase (note that the
                  screening serumblood pregnancy test can be used as the test prior to the start of
                  study treatment in the Treatment Phase if it is performed within the 72 hour
                  timeframe).

          -  Men must use a latex condom during any sexual contact with women of childbearing
             potential

          -  Willing to adhere to protocol specific requirements

          -  Clinically significant toxic effects of prior therapy (except hydroxyurea) resolved to
             grade =< 1 before the start of study

          -  Participant or legal representative must understand the investigational nature of this
             study and sign an Independent Ethics Committee/Institutional Review Board approved
             written informed consent form prior to receiving any study related procedure

        Exclusion Criteria:

          -  Acute promyelocytic leukemia (APL)

          -  Subject has or is suspected of having central nervous system (CNS) leukemia.
             Evaluation of cerebrospinal fluid is only required if CNS involvement by leukemia is
             suspected during screening

          -  Clinically active or unstable graft-versus-host disease (GVHD) requiring treatment
             that precludes administration of chemotherapy as defined in this protocol

          -  Prior anti-leukemia therapy within 5 x the half-life for other investigational agents

               -  Prior use of hydroxyurea or isolated doses of cytarabine for palliation (i.e.,
                  control of white blood count [WBC]) are allowed but should be discontinued at
                  least 24 hours prior to enrollment. Other agents used strictly with palliative
                  intent might be allowed during this period after discussing with principal
                  investigator

          -  Pre-existing liver disease (e.g. cirrhosis, chronic hepatitis B or C, nonalcoholic
             steatohepatitis, sclerosing cholangitis)

          -  Subject is known seropositive or active infection with human immunodeficiency virus
             (HIV), or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)

          -  Subject has active uncontrolled systemic fungal, bacterial, or viral infection
             (defined as ongoing signs/symptoms related to the infection without improvement
             despite appropriate antibiotics, antiviral therapy, and/or other treatment)

          -  Pregnant or nursing female participants

          -  Subjects of childbearing potential not willing to use adequate contraception

          -  Subject has significant active cardiac disease within 6 months prior to the start of
             study treatment, including New York Heart Association (NYHA) class III or IV
             congestive heart failure; acute coronary syndrome (ACS); and/or stroke; or left
             ventricular ejection fraction (LVEF) < 40% by echocardiogram (ECHO) or multi-gated
             acquisition (MUGA) scan obtained within 28 days prior to the start of study treatment

          -  Subject with concurrent severe and/or uncontrolled medical or psychiatric conditions
             that in the opinion of the investigator may impair the participation in the study or
             the evaluation of safety and/or efficacy

          -  Subject has immediately life-threatening, severe complications of leukemia such as
             uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated
             intravascular coagulation

          -  Subject is known to have dysphagia, short-gut syndrome, gastroparesis, or other
             conditions that limit the ingestion or gastrointestinal absorption of drugs
             administered orally

          -  Subjects has uncontrolled hypertension (systolic blood pressure [BP] > 180 mmHg or
             diastolic BP > 90 mmHg)

          -  Subject has known (or suspected to have) hypersensitivity to any of the components of
             study treatment

          -  Subject has corrected QT (QTc) interval (i.e., Fridericia's correction [QTcF]) >= 450
             ms or other factors that increase the risk of QT prolongation or arrhythmic events
             (e.g., heart failure, hypokalemia, family history of long QT interval syndrome) at
             screening

          -  Subject is taking the following sensitive CYP substrate medications that have a narrow
             therapeutic range are excluded from the study unless the subject can be transferred to
             other medications at least 5 half-lives prior to the start of study treatment:
             phenytoin (CYP2C9), S-mephenytoin (CYP2C19), thioridazine (CYP2D6), theophylline, and
             tizanidine (CYP1A2)

          -  Subject who is taking the breast cancer resistance protein (BCRP)
             transporter-sensitive substrate (i.e., rosuvastatin) should be excluded from the study
             unless the subject can be transferred to other medications at least 5 half-lives prior
             to the start of study treatment

          -  Subject with prior history of malignancy, other than myelodysplastic syndrome (MDS),
             myeloproliferative neoplasm (MPN) or AML may be eligible after discussion with the
             study doctor. Diagnoses of basal or squamous cell carcinoma of the skin, carcinoma in
             situ of the cervix, carcinoma in situ of the breast, and previously treated prostate
             cancer (T1a/T1b by TNM staging) are not exclusionary :

          -  Concurrent participation in another therapeutic clinical trial

          -  Unwilling or unable to follow protocol requirements

          -  Any condition which in the investigator's opinion deems the participant an unsuitable
             candidate to receive study drug Subject has any condition including the presence of
             laboratory abnormalities, which places the subject at unacceptable risk if he/she were
             to participate in the study.